Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2014-11-06 Interim / Quarterly Rep…
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report 9M 2014
2014-11-06 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes an announcement of the appointment of a new President and Chief Scientific Officer, which is a change in senior management. It also references a press release about financial results but does not contain the financial results itself. The primary focus is on management changes, not on financial reporting or earnings release. Therefore, the document fits best under Board/Management Information (MANG). The document length is about 5407 characters, which is sufficient to contain substantive information about management changes rather than just a brief announcement or reference to another report.
2014-11-06 English
FORM 3/A SUBMISSION
Director's Dealing
2014-09-26 English
FORM 3/A SUBMISSION
Director's Dealing
2014-09-26 English
S-8
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities to be offered under employee benefit plans such as equity incentive plans. It includes details about the securities to be registered, indemnification provisions, incorporation by reference of other filings, and exhibits related to the equity incentive plan. This is not a financial report, earnings release, or management discussion, but a registration statement related to share issuance under an equity plan. According to the filing definitions, announcements or filings related to new share issues or capital changes fall under 'Share Issue/Capital Change' (SHA). Therefore, this document is best classified as a Share Issue/Capital Change filing.
2014-09-15 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated September 4, 2014. It specifically mentions Regulation FD Disclosure and states that the company is presenting at the Baird 2014 Health Care Conference. The key content is the presentation materials intended for the conference, furnished as Exhibit 99.1. The document explicitly states that the presentation materials are being furnished and incorporated by reference, and the company disclaims any obligation to update the presentation. This indicates the document is primarily an investor presentation rather than a full financial report or earnings release. The length of the document is 3787 characters, which is relatively short and consistent with a presentation filing rather than a full report. Therefore, the most appropriate classification is Investor Presentation (IP).
2014-09-04 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.